132 related articles for article (PubMed ID: 29549809)
21. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Toma A; Kosmider O; Chevret S; Delaunay J; Stamatoullas A; Rose C; Beyne-Rauzy O; Banos A; Guerci-Bresler A; Wickenhauser S; Caillot D; Laribi K; De Renzis B; Bordessoule D; Gardin C; Slama B; Sanhes L; Gruson B; Cony-Makhoul P; Chouffi B; Salanoubat C; Benramdane R; Legros L; Wattel E; Tertian G; Bouabdallah K; Guilhot F; Taksin AL; Cheze S; Maloum K; Nimuboma S; Soussain C; Isnard F; Gyan E; Petit R; Lejeune J; Sardnal V; Renneville A; Preudhomme C; Fontenay M; Fenaux P; Dreyfus F
Leukemia; 2016 Apr; 30(4):897-905. PubMed ID: 26500139
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
Raza A; Galili N; Smith SE; Godwin J; Boccia RV; Myint H; Mahadevan D; Mulford D; Rarick M; Brown GL; Schaar D; Faderl S; Komrokji RS; List AF; Sekeres M
Cancer; 2012 Apr; 118(8):2138-47. PubMed ID: 21887679
[TBL] [Abstract][Full Text] [Related]
24. Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.
Wesa KM; Cunningham-Rundles S; Klimek VM; Vertosick E; Coleton MI; Yeung KS; Lin H; Nimer S; Cassileth BR
Cancer Immunol Immunother; 2015 Feb; 64(2):237-47. PubMed ID: 25351719
[TBL] [Abstract][Full Text] [Related]
25. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Garcia-Manero G; Khoury HJ; Jabbour E; Lancet J; Winski SL; Cable L; Rush S; Maloney L; Hogeland G; Ptaszynski M; Calvo MC; Bohannan Z; List A; Kantarjian H; Komrokji R
Clin Cancer Res; 2015 Mar; 21(5):985-94. PubMed ID: 25480830
[TBL] [Abstract][Full Text] [Related]
27. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.
Santini V; Valcárcel D; Platzbecker U; Komrokji RS; Cleverly AL; Lahn MM; Janssen J; Zhao Y; Chiang A; Giagounidis A; Guba SC; Gueorguieva I; Girvan AC; da Silva Ferreira M; Bhagat TD; Pradhan K; Steidl U; Sridharan A; Will B; Verma A
Clin Cancer Res; 2019 Dec; 25(23):6976-6985. PubMed ID: 31481511
[TBL] [Abstract][Full Text] [Related]
28. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
29. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
30. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
Steensma DP; Fenaux P; Van Eygen K; Raza A; Santini V; Germing U; Font P; Diez-Campelo M; Thepot S; Vellenga E; Patnaik MM; Jang JH; Varsos H; Bussolari J; Rose E; Sherman L; Sun L; Wan Y; Dougherty S; Huang F; Feller F; Rizo A; Platzbecker U
J Clin Oncol; 2021 Jan; 39(1):48-56. PubMed ID: 33108243
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
32. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
Chan O; Komrokji RS
Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
[TBL] [Abstract][Full Text] [Related]
33. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
Raza A; Galili N; Callander N; Ochoa L; Piro L; Emanuel P; Williams S; Burris H; Faderl S; Estrov Z; Curtin P; Larson RA; Keck JG; Jones M; Meng L; Brown GL
J Hematol Oncol; 2009 May; 2():20. PubMed ID: 19439093
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
[TBL] [Abstract][Full Text] [Related]
36. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
[TBL] [Abstract][Full Text] [Related]
37. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
[TBL] [Abstract][Full Text] [Related]
38. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
Daher M; Hidalgo Lopez JE; Randhawa JK; Jabbar KJ; Wei Y; Pemmaraju N; Borthakur G; Kadia T; Konopleva M; Kantarjian HM; Hearn K; Estrov Z; Reyes S; Bueso-Ramos CE; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):674-682. PubMed ID: 28370157
[TBL] [Abstract][Full Text] [Related]
39. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
40. Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes.
Hirano T; Hiratsuka N; Iwahori T; Oka K; Wakasugi K
Res Commun Mol Pathol Pharmacol; 2003; 113-114():315-28. PubMed ID: 15686130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
